FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer

Mitchell S. Anscher, Elaine Chang, Xin Gao, Yutao Gong, Chana Weinstock, Erik Bloomquist, Oluseyi Adeniyi, Rosane Charlab, Sarah Zimmerman, Maritsa Serlemitsos-Day, Yang Min Ning, Ruth Mayrosh, Barbara Fuller, Ann Marie Trentacosti, Pamela Gallagher, Karen Bijwaard, Reena Philip, Soma Ghosh, Frances Fahnbulleh, Felicia DiggsShaily Arora, Kirsten B. Goldberg, Shenghui Tang, Laleh Amiri-Kordestani, Richard Pazdur, Amna Ibrahim, Julia A. Beaver

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences